Novavax appoints senior vp of business development

Russell ‘Rip’ Wilson takes the role at US biopharmaceutical firm

US biopharmaceutical firm Novavax has appointed Russell ‘Rip’ Wilson as senior vice president of business development. He takes responsibility for developing business alliances, licensing arrangements, and partnering opportunities with pharmaceutical companies and government agencies.

Wilson was most recently chief financial officer at Supernus Pharmaceuticals. He was previously senior vice president, chief financial officer and general counsel of Iomai Corporation, which was acquired in 2008 by Intercell. He was also the acting general counsel of North American Vaccine, until its acquisition by Baxter International in 2000.

You may also like

Manufacturing

Novavax sells protein manufacturing facility to Novo Nordisk for $200m

Novo Nordisk's purchase of Novavax's Czech recombinant protein manufacturing facility will involve a full transfer of assets — including its workforce and associated support buildings
Manufacturing

Ardena expands capacity for COVID vaccine production

The expansion follows the grant of conditional marketing authorisation by the European Commission for Novavax’s Nuvaxovid COVID-19 vaccine
Research & Development

US HHS awards influenza contracts worth US$215m

Novavax and VaxInnate to develop VLP and recombinant influenza vaccines, respectively
Regulatory

FDA clears Novavax RSV vaccine candidate for early stage trial

Novavax resolves question about chemistry, manufacturing and controls
Research & Development

Novavax terminates negotiations with ROVI Pharmaceuticals

US biotech Novavax has ended talks aimed at negotiating the terms of a collaboration with Spanish drugmaker ROVI Pharmaceuticals to develop Novavax\'s virus-like-particle (VLP)-based vaccines against influenza.
Manufacturing

Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair

Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing

BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany

The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
Subscribe now